Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

29.2%

7 terminated/withdrawn out of 24 trials

Success Rate

68.2%

-18.3% vs industry average

Late-Stage Pipeline

21%

5 trials in Phase 3/4

Results Transparency

53%

8 of 15 completed trials have results

Key Signals

2 recruiting8 with results6 terminated

Enrollment Performance

Analytics

Phase 2
9(39.1%)
Phase 1
9(39.1%)
Phase 3
5(21.7%)
23Total
Phase 2(9)
Phase 1(9)
Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT04931667Phase 3Terminated

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

Role: lead

NCT04520607Phase 3Terminated

A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

Role: lead

NCT03706521Phase 2Terminated

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

Role: lead

NCT03928184Phase 3Completed

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

Role: lead

NCT04385303Phase 3Completed

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

Role: lead

NCT03727022Phase 2Completed

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Role: lead

NCT07155200Phase 1Recruiting

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Role: collaborator

NCT07032285Phase 2Recruiting

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Role: collaborator

NCT03355066Phase 1Terminated

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Role: lead

NCT05084859Phase 1Terminated

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Role: lead

NCT05603754Phase 3Completed

A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Role: lead

NCT03742518Phase 2Completed

A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Role: lead

NCT03122860Phase 2Completed

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Role: lead

NCT02536833Phase 2Completed

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Role: lead

NCT04598542Phase 1Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Role: lead

NCT02951026Completed

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Role: lead

NCT02275351Phase 2Completed

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Role: lead

NCT02503137Phase 2Completed

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Role: lead

NCT03246399Phase 1Terminated

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

Role: lead

NCT03591926Phase 2Withdrawn

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead